For cancer-free AJ women the probability of having a pathogenic mutation in CHEK2 is 1.4%–1.7% and the chance for a mutation in BRCA1 or BRCA2 is less than 2.5% (Walsh et al., 2017). Here, CHEK2 is linked to cancer.